SOPHiA GENETICS Chief Legal Officer Van Well Daan sold 6,168 shares at $7.63 per share on 2026-09-11. The transaction represented about 1.8% of Daan’s prior holding, while ownership after the sale stood at 338,884 shares, giving investors the disclosed scale of the insider reduction.
Key Highlights
- Van Well Daan owned 338,884 SOPHiA GENETICS shares after the transaction.
- The sale represented about 1.8% of Van Well Daan’s prior shareholding.
- SOPHiA GENETICS Chief Legal Officer Van Well Daan sold 6,168 shares at $7.63 per share.
SOPHiA GENETICS SA (NASDAQ: SOPH) Chief Legal Officer Van Well Daan sold 6,168 shares at $7.63 per share. The transaction took place on 11 September 2026.
Insider Sale Details
Van Well Daan serves as SOPHiA GENETICS’ Chief Legal Officer. The transaction involved 6,168 shares of SOPHiA GENETICS at a price of $7.63 per share. Transaction code S identifies the deal as an open-market sale.
Remaining Holding and Transaction Scale
Van Well Daan owned 338,884 shares after completing the sale. The transaction represented about 1.8% of the prior shareholding.
FAQs
Q: What did Van Well Daan sell in SOPHiA GENETICS?
A: SOPHiA GENETICS Chief Legal Officer Van Well Daan sold 6,168 shares at $7.63 per share. The transaction occurred on 11 September 2026.
Q: How many SOPHiA GENETICS shares did Van Well Daan own after the sale?
A: Van Well Daan owned 338,884 SOPHiA GENETICS shares after the insider transaction. The sale represented about 1.8% of the prior shareholding.
Q: Was the SOPHiA GENETICS insider transaction an open-market sale?
A: Yes. The filing identifies transaction code S for Van Well Daan’s sale of 6,168 SOPHiA GENETICS shares at $7.63 per share. This code describes the transaction as an open-market sale.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.